Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32-35 weeks' gestational age with more informed use of risk factors?

J Matern Fetal Neonatal Med. 2015 Jul;28(10):1133-41. doi: 10.3109/14767058.2014.947573. Epub 2014 Aug 14.

Abstract

Objective: To evaluate the key risk factors for respiratory syncytial virus (RSV) hospitalisation in 32-35 weeks' gestational age (wGA) infants.

Methods: Published risk factors were assessed for predictive accuracy (area under the receiver operating characteristic curve [ROC AUC]) and for number needed to treat (NNT).

Results: Key risk factors included: proximity of birth to the RSV season; having siblings; crowding at home; day care; smoking; breast feeding; small for GA; male gender; and familial wheezing/eczema. Proximity of birth to the RSV season appeared the most predictive. Risk factors models from Europe and Canada were found to have a high level of predictive accuracy (ROC AUC both > 0.75; NNT for European model 9.5). A model optimised for three risk factors (birth ± 10 weeks from start of RSV season, number of siblings ≥ 2 years and breast feeding for ≤ 2 months) had a similar level of prediction (ROC AUC: 0.776; NNT: 10.2). An example two-risk factor model (day care attendance and living with ≥ 2 siblings < 5 years old) had a lower level of predictive accuracy (ROC AUC: 0.55; NNT: 26).

Conclusions: An optimised combination of risk factors has the potential to improve the identification of 32-35 wGA infants at heightened risk of RSV hospitalisation.

Keywords: Bronchiolitis; NNT; hospitalisation; palivizumab; premature infants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Area Under Curve
  • Female
  • Gestational Age
  • Hospitalization
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature*
  • Male
  • Numbers Needed To Treat
  • Respiratory Syncytial Virus Infections / etiology
  • Respiratory Syncytial Virus Infections / prevention & control*
  • Respiratory Syncytial Viruses*
  • Risk Assessment
  • Risk Factors

Substances

  • Antiviral Agents